• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing
  3. / Healthcare

Kindred: Potential in Animal Healthcare

Two commercially-viable products could spur enormous growth.
By SHAM GAD May 09, 2014 | 11:30 AM EDT
Stocks quotes in this article: KIN

While investing is a highly -egulated industry, in terms of how an investor chooses to pick and make his investment decisions, it also is a field with a wide degree of latitude. You can copy another's work -- in fact piggybacking on another investor's idea is considered a prudent approach.

You can also buy and sell the same stock more than once. Indeed, security price is the single most important component that determines the future return. Indeed, this market will allow patient investors to do just that.

For example, Kindred Biosciences (KIN) is a name I first mentioned several months ago back in January. Kindred is a biotech focused on animal healthcare. We have hundreds of biotechs that create human drugs. Kindred is attempting to do the same for animals and really the only pure play company in the industry at the moment. Specifically, the company is focusing on treatments for cats, dogs and horses.

At the time, the stock was trading for around $13.50. Within a month, the shares had zoomed to $26. I owned Kindred at $13, didn't sell at $26, and now the shares are trading back at $14.60. Naturally, I wish I were smart enough to have sold in February and bought shares again now. Nothing of any significance has led to the selloff. In April, the company did an equity rights offering that was oversubscribed at an offering price of $18 per share.

Kindred is still on track and expects approval for CareKin, a treatment for canine osteoarthritis, in the second half of 2015. This product is also showing signs of efficacy for horses and cats. Another candidate AtoKin, a treatment for canine dermatitis, is expected to be approved by the end of 2015. Kindred also has several other candidates moving through its pipeline.

The decline in stock price opens up another door to invest at an attractive price. The next earnings report is due out next Monday and it will be your typical biotech report. Because the company has no commercial products out yet, there will be a cash burn. It's possible another stock offering will occur in the future to raise cash. But unlike traditional human biotechs, animal drugs cost a fraction to bring to market and have a much shorter window from development to commercial approval.

The stock price has come back nicely, but is still off from the IPO price of approximately $9. But at the current price, Kindred has a market cap of $233 million. Were the company to have a couple of commercially-viable products in its stable, Kindred could become a billion dollar enterprise very quickly.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication Gad was long KIN

TAGS: Investing | U.S. Equity | Healthcare

More from Healthcare

There Are Market Bright Spots, but I View the July Rally as a Head Fake

Bret Jensen
Aug 3, 2022 10:30 AM EDT

It's hard to see stock valuations rising when inflation remains high and the economy appears headed for a recession if it isn't in one already.

A Recession Appears Inevitable, but There Are Still Places to Invest

Bret Jensen
Jul 27, 2022 10:30 AM EDT

A few homebuilders and healthcare stocks seem likely to hold up better than most of the market in a recession.

Change Healthcare Continues to Knock on a Breakout Level

Bruce Kamich
Jul 25, 2022 11:25 AM EDT

The CHNG chart is at an interesting juncture.

The Healing Process Begins for Cano Health

Bruce Kamich
Jul 21, 2022 1:30 PM EDT

Here's how to approach CANO as the shares have made a bottom formation.

With HCA Healthcare, I'm Getting Healthy Indications

Bruce Kamich
Jul 21, 2022 9:20 AM EDT

The healthcare provider is set to report earnings Friday.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 08:44 AM EDT PETER TCHIR

    CPI Beats Expectations, But Maybe Not the 'Whisper'?

    Slightly better-than-expected inflation across the...
  • 01:44 PM EDT STEPHEN GUILFOYLE

    This Holding Lights Up With Strong Earnings

    Check out the latest from TheStreet's Stocks Under...
  • 09:24 AM EDT PETER TCHIR

    Jobs Report Reaction: Incredibly Strong, But Questions to Ask

    An incredibly strong July jobs report. Not only d...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login